glofitamab,rituximab
roche
['dlbcl', 'glofitamab', ' ipi ']
high response rates observed with the combination rchop+glofitamab in 1l dlbcl patients. mandatory hospitalization during step up was removed according to safety run-in results. no icans was observed #ash22 #immunotherapy #bites #glofitamab 
Hematologist, MD
Vall d'Hebron Hospital